#India #Mumbai #Piramal Pharma #Piramal Solutions #Piramal Healthcare

Overview of Piramal Pharma's Annual Report for FY2026

In its recently published FY2026 Annual Report, Piramal Pharma Limited (PPL), a key player in the pharmaceutical and health sectors, highlighted its international footprint, innovation-driven growth, and significant strides in sustainability. PPL, which operates under ticker symbols NSE: PPLPHARMA and BSE: 543635, made clear its ongoing commitment to improving patient outcomes through scientific innovation and operational excellence.

Financial Performance and Growth

For FY2026, Piramal Pharma reported an operating revenue of ₹8,869 crores. This substantial figure is attributed to the company’s diversified economic model, bolstered by 17 development and manufacturing sites globally and commercial presence in over 100 countries. Notably, around 66% of this revenue was generated in regulated markets, underscoring the company's robust global operations.

Nandini Piramal, the chairperson of Piramal Pharma, remarked, "The financial year 2026 was a year of transition in which we faced external disruptors alongside internal factors. However, we have positioned ourselves positively across all three business sectors due to enhanced execution and visibility into our growth trajectory."

Key Business Units and Strategic Initiatives

1. Piramal Pharma Solutions (CDMO): This segment, which contributes 55% of PPL's total revenue, has established itself as a leading global provider of integrated manufacturing and development services. Serving over 500 international clients within the pharmaceutical and biotech industries, this division is pivotal to PPL's growth strategy. Additionally, the company has committed to investing $90 million in sterile injectable products and payload links as part of its strategic plans.

2. Piramal Critical Care (CHG): This division solidified its leadership position in the U.S. inhalation anesthesia market, particularly with sevoflurane. The segment also concluded the acquisition of Kenalog, while continuing to furnish services to over 6,000 hospitals, surgical centers, and clinics globally.

3. Piramal Consumer Healthcare: With reported revenues of ₹1,274 crores, this branch has enriched its portfolio to include more than 25 consumer health brands. During FY2026, it launched 31 new products, and key brands experienced a remarkable 24% growth, contributing 52% to Piramal Consumer Healthcare's total revenues.

Emphasis on Quality and Compliance

Quality assurance is a cornerstone of Piramal Pharma’s operations. In FY2026, the company successfully underwent 38 regulatory inspections, including three conducted by the U.S. FDA, without any observations leading to formal actions, illustrating the robustness of its quality systems and compliance standards.

Commitment to Sustainability

Piramal Pharma made significant advancements in its sustainability initiatives, particularly following the approval of its science-based decarbonization roadmap. The company recorded a 22.6% reduction in scope 1 and 2 greenhouse gas emissions when compared to the FY2022 baseline.

Focus on People and Safety

With a global workforce exceeding 7,285 employees, Piramal Pharma has placed a strong emphasis on a people-centric culture while maintaining a firm commitment to workplace safety, evidenced by a zero fatality record for the past five years.

For more detailed insights and performance indicators, the complete report is accessible via Piramal Pharma’s official site.

Piramal Pharma Limited offers a differentiated range of products and services derived from its 17 development and manufacturing sites worldwide, alongside a distribution network that spans over 100 countries. The company’s segments include Piramal Pharma Solutions, Piramal Critical Care, and Piramal Consumer Healthcare. It also holds a strategic minority investment in Yapan Bio Private Limited in the biologics/biotherapeutics and vaccines segment.

For further information, visit Piramal Pharma on LinkedIn.